004064de-0e10-491d-b3d8-bc628a8f70a8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- MYC_TARGETS_V1+0.600
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V2+0.500
- OXIDATIVE_PHOSPHORYLATION+0.500
- UNFOLDED_PROTEIN_RESPONSE+0.400
- DNA_REPAIR+0.300
- MITOTIC_SPINDLE+0.300
- MTORC1_SIGNALING+0.300
- PI3K_AKT_MTOR_SIGNALING+0.300
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- ANGIOGENESIS-0.400
- APICAL_SURFACE-0.400
- COAGULATION-0.400
- COMPLEMENT-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088859 | — | — | 0.940 |
| 2 | ERR2598206 | fetal | fetal | 0.919 |
| 3 | TCGA-DK-A3X2-01A-11R-A22U-07 | — | — | 0.917 |
| 4 | TCGA-XF-A9ST-01A-11R-A42T-07 | — | — | 0.914 |
| 5 | TCGA-85-8070-01A-11R-2247-07 | — | cohortSQ2 | 0.911 |
| 6 | SRR12202462 | — | — | 0.909 |
| 7 | SAMN03290931 | — | — | 0.909 |
| 8 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.908 |
| 9 | TCGA-GC-A4ZW-01A-11R-A26T-07 | — | — | 0.905 |
| 10 | TCGA-60-2711-01A-01R-0851-07 | — | cohortSQ2 | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |